Titong, Allison
Gallolu Kankanamalage, Sachith
Dong, Jianbo
Huang, Betty
Spadoni, Nicholas
Wang, Bo
Wright, Meredith
Pham, Keegan L. J.
Le, Anh Hai
Liu, Yue
Article History
Received: 19 November 2021
Accepted: 23 February 2022
First Online: 9 March 2022
Competing interests
: All authors of this study are current or former employees at Ab Studio Inc. that commercially develops therapeutic antibodies. In addition, Yue Liu serves as the Chief Executive Officer at Ab Therapeutics inc., that also commercially develops therapeutic antibodies.